Funding for development of new strategies to treat and prevent Hepatitis C virus | UNIVERSITY OF PLYMOUTH

Hepatitis C virus (HCV) is a major global pathogen with more than 160 million people worldwide are chronically infected by the disease. Left untreated HCV will progress to severe liver disease, cirrhosis and liver cancer.

HCV-related deaths worldwide annually exceed 350,000, comparable to AIDS, TB and malaria. In high-income countries HCV accounts for substantially more deaths than all three of these diseases combined, and is the most common reason for liver transplantation in the UK where there are believed to be 350,000 chronic HCV carriers.

The burden of HCV disease falls on the poor. Current drug treatments are prohibitively expensive even within the UK, and have limiting side effects and achieve sustained clearance of the virus in only 50 to 60% of patients.

Read more


Insurance company’s action could mean big things for Hepatitis C sufferers | JoAnn Seltzer

SAN FRANCISCO — More patients will have access to a life-saving medicine after a decision was made recently by a large insurer.

According to Modern Healthcare, Blue Shield Life and Health and Blue Shield of California was facing a class-action suit in Northern California after it initially denied a costly Hepatitis C medicine to some patients. The lawsuit was dismissed by a federal judge last week after Blue Shield decided to expand coverage on the drug Harvoni. Previously, the company only covered the medicine for the sickest patients.

Ryan Clary, executive director of The National Viral Hepatitis Roundtable, told The Northern California Record he believes everyone who has Hepatitis C who wants to be cured and has insurance and a provider willing to treat them should have access to the medicine.

Read more


Organ Transplants Hit A Record High For A Very Depressing Reason A lot of lives are being saved by drug overdose deaths | Erin Schumaker Senior Healthy Living Editor, The Huffington Post

Organ transplants in the United States rose 9 percent between 2015 and 2016, reaching a record peak of 33,606 transplants, according to the United Network for Organ Sharing.

That increase comes on the heels of a 20 percent gain in organ donations since 2012. The record high for transplants is partly the result of rule changes over time that have allowed a wider spectrum of donors ― including people of advanced age or with behavioral risk factors such as drug use or tattoos, who used to be disqualified.

More recently, the spike in transplants is linked to a public health problem that has led to the premature death of many young people: the opioid crisis.

Read more


Efficacy and Safety of MK-3682 + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

This is a nonrandomized (participants may decide which drugs they want to take), multi-site, open-label trial to evaluate a novel two-drug combination regimen (MK-3682 450 mg + ruzasvir [RZR; MK-8408] 180 mg once daily [q.d.] for 12 weeks) in male and female treatment-naïve (TN taken once-a-dayj) or treatment-experienced (TE) participants with chronic hepatitis C virus (HCV) infection genotype (GT) GT1, GT2, GT3, GT4, GT5, or GT6 who have not previously received HCV direct-acting antiviral (DAA) therapy. Cirrhotic (C) and non-cirrhotic (NC) participants with and without human immunodeficiency virus (HIV) co-infection will be enrolled.

Efficacy and Safety of MK-3682 + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

To read the entire clinical trial description, click here


FDA Encourages More Participation, Diversity in Clinical Trials

FDA Encourages More Participation, Diversity in Clinical Trials

Diversity in clinical trials (600x400)

Get Consumer Updates by E-mail

Clinical trials are voluntary human research studies designed to answer specific questions about the safety and effectiveness of drugs, vaccines, devices, and other therapies—or to study new ways of using existing treatments.

The U.S. Food and Drug Administration does not ordinarily conduct clinical trials. But the FDA relies on the data from these trials to determine whether medical products are safe and effective.

Overall, few people actually sign up for and participate in trials, and those who do participate don’t always represent the U.S. population. Participation is especially low for certain populations, including adults age 75 or older and people from certain racial and ethnic groups. That’s why the FDA is encouraging more patients to participate in clinical trials, especially people of different ages, races, ethnic groups, and genders.

Read on to learn more about why.

Why is diversity important?

Clinical trials, and the people who volunteer to participate in them, are essential to help the development of ways to fight illnesses.

To make sure that the FDA has a full picture of the risk or benefit of a medical product, patients enrolled in a trial should be representative of the types of patients who are likely to use the medical product if it is approved or cleared by the FDA.

Certain populations can be more at risk for certain diseases—such as diabetes and heart disease—than others. So it is important for patients in those populations who are more likely to be treated for a condition to be included in a trial.

And experience has shown that there can be important differences in how people of diverse groups respond to medical products. Information on those differences can then be included in the product labeling to help doctors and patients make treatment decisions.

The bottom line? Researchers should test medical products in all groups of people to help ensure medical products are safe and effective in everyone who will use them. That’s why diversity in clinical trials is essential.

Why don’t more people participate?

There are many reasons why so few people, including patients, and fewer diverse patients, participate in clinical trials. For instance, few doctors who see patients also conduct clinical research. And it may be difficult for some patients to find the time or have the resources to get to a trial site.

Since medical products are developed globally (with many clinical trials conducted outside the United States), these trials may not include the diversity of the U.S. population.

Some U.S. patients also may not trust medical research due to historical mistreatment of study subjects, such as those involved in the Tuskegee Study, which began in 1932 and continued for 40 years. That study’s serious flaws led to major changes in how clinical trials are conducted in order to protect the rights, safety, and welfare of patients in clinical trials.

Today, participants’ rights are protected by law and by committees such as “institutional review boards.” These ethics committees, also known as “IRBs,” are independent from the people conducting the study. IRBs carefully review plans for research involving people before research can be conducted and at least once a year while research is conducted.

Do clinical trials have possible risks and benefits?


Sometimes patients enroll in a clinical trial to get early access to what they believe is a promising therapy. However, there are no guarantees that the therapy will work or that they will be assigned to the group of patients who receive the therapy under study. They instead may be assigned to a comparison group that receives another approved treatment or placebo. Either way, they will likely receive the highest standard of current care for their condition, will be asked to undergo various tests, and could be required to come back to the clinic for repeat visits.

But clinical trials also can carry serious risks—an important fact to consider. Participants learn about known risks during the informed consent process, but sometimes risks are not known until clinical trials are under way or completed.

The FDA is committed to protecting participants of clinical trials and to ensuring that people have reliable information when they decide whether to participate.

You can learn more about these topics on the FDA webpage “Inside Clinical Trials: Testing Medical Products in People.”

What are some related FDA regulations?

FDA regulations require product developers who submit applications for medical products to analyze clinical trial data by sex, age, and race. The FDA expects medical product research to reflect the relevant science.

In public comments and guidance to drug companies and FDA staff, the agency encourages inclusion of more diverse participants. But the FDA also understands that in certain instances it would not be appropriate for sponsors to have participants that represent the population. This is partly because some products or treatments are intended for only certain people. (Examples include gynecological products for women and products to treat prostate cancer in men.)

Okay, so what else is the FDA doing to encourage diversity?

The FDA is working with a variety of stakeholders, including federal partners, medical product manufacturers, medical professionals, and health advocates.

For example, the FDA has a dedicated section on its website for patients that provides information and tools to encourage clinical trial participation. This section includes information that focuses on people of different ages, races, ethnic groups, and genders.

The FDA’s Office of Women’s Health, along with the National Institutes of Health (NIH) Office for Research on Women’s Health, launched an initiative to raise awareness among women and share best practices for clinical trials.

The FDA’s Office of Minority Health also has tools to encourage people and their health care providers to learn about trials, including public service announcements (PSAs). (You can view PSAs on the FDA’s “Minorities in Clinical Trials” webpage.)

And the FDA offers guidance for researchers as appropriate, including recent recommendations to industry and agency staff on how race and ethnicity data should be collected.

What else should I know? And where can I find a clinical trial?

Many people volunteer for clinical trials to help others. So, although you may not directly benefit during a clinical trial, the information collected can add to scientific knowledge and help with future research and product development. (Remember that there are potential benefits and risks to participating in a clinical trial. And there are no guarantees.)

You can talk to your health care provider to find out if a clinical trial may be right for you.

NIH also keeps a list of ongoing trials, so you can search for studies at All clinical trials specify who is eligible to participate, and participants must be accepted before joining.

Finally, remember that you can learn more about clinical trials and diversity on the FDA’s webpage: “Clinical Trials: What Patients Need to Know.”

This article appears on the FDA’s Consumer Updates page, which features the latest on all FDA-regulated products.

January 10, 2016


Hepatitis Status May Impact HCC Treatment Efficacy

HealthDay News — For patients with advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival (OS) is dependent on patients’ hepatitis status, according to a meta-analysis published online in the Journal of Clinical Oncology.

Richard Jackson, from the Liverpool Cancer Trials Unit in the United Kingdom, and colleagues undertook an individual patient data meta-analysis of three prospective randomized trials in which sorafenib was the control arm. Data were included for 1,643 patients with advanced unresectable hepatocellular carcinoma who received sorafenib.

The researchers found that patients who were both hepatitis B virus (HBV) negative and hepatitis C virus (HCV) positive had improved OS for sorafenib (log [hazard ratio], −0.27). In this subgroup, the median unadjusted survival was 12.6 and 10.2 months for sorafenib and other treatments, respectively. Other patient subgroups defined by HBV and HCV did not have improvement in OS. Consistent results were seen across all trials.

Read more


Antiviral Drug Prevents Recurrence of Hepatitis C in Liver Transplant Patients | ANNA WILLIAMS

Patients with hepatitis C virus infection who received an antiviral drug around the time they underwent liver transplantation saw a high rate of sustained virologic response, according to a Northwestern Medicine phase II clinical trial. The finding suggests that the therapy might be an effective approach to preventing reinfection in such patients.

Josh Levitsky, MD, MS, professor of Medicine in the Division of Gastroenterology and Hepatology, was the corresponding author of the paper, published in the New England Journal of Medicine.

Infection with the blood-borne hepatitis C virus (HCV) can lead to severe liver damage. As such, HCV-associated cirrhosis is currently the leading indication for liver transplantation. But because almost all patients with the virus experience a recurrence of infection after they receive a transplant, there tend to be high rates of graft failure.

Read more